anonymous
Guest
anonymous
Guest
Novo Nordisk ($NVO) finally launched its next-gen diabetes treatment Tresiba in the U.S., approved by the FDA last September. The Danish drugmaker has high hopes for sales, but the long-acting insulin faces new competitors that could get in the way of those ambitions.
Novo Nordisk CEO Lars Rebien Sørensen
Tresiba will go up against Sanofi's ($SNY) market standby Lantus and its newly approved follow-up Toujeo. Plus, as of December, it will face lower-priced competition from Eli Lilly ($LLY) and Boehringer Ingelheim, in the form of their Lantus biosimilar Basaglar.
Still, Novo sees advantages to Tresiba, and it's fielding a large, experienced salesforce to get those advantages across. CEO Lars Rebien Sørensen has said that payer contracts will be key to Tresiba's market share battle with Toujeo. Sanofi is pushing hard to move patients onto the longer-acting Toujeo before Lilly and BI's biosim hits the market.
Novo Nordisk CEO Lars Rebien Sørensen
Tresiba will go up against Sanofi's ($SNY) market standby Lantus and its newly approved follow-up Toujeo. Plus, as of December, it will face lower-priced competition from Eli Lilly ($LLY) and Boehringer Ingelheim, in the form of their Lantus biosimilar Basaglar.
Still, Novo sees advantages to Tresiba, and it's fielding a large, experienced salesforce to get those advantages across. CEO Lars Rebien Sørensen has said that payer contracts will be key to Tresiba's market share battle with Toujeo. Sanofi is pushing hard to move patients onto the longer-acting Toujeo before Lilly and BI's biosim hits the market.